<DOC>
	<DOCNO>NCT01401114</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient receive Wellnara postmenopausal osteoporosis . The objective study ass safety efficacy use Wellnara clinical practice . A total 400 patient recruit follow 3 year since start Wellnara administration .</brief_summary>
	<brief_title>Wellnara Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Patients receive Wellnara postmenopausal osteoporosis Patients contraindicate base product label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Wellnara</keyword>
	<keyword>Postmenopausal osteoporosis</keyword>
</DOC>